Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
0 hedge funds and large institutions have $0 invested in Ibere Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.
100% less funds holding
Funds holding: 47 → 0 (-47)
100% less capital invested
Capital invested by funds: $126M → $0 (-$126M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 47
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$13.4M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$7.93M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$7.23M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$6.85M |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$6.81M |
IBER Hedge Fund Activity: Q1 2023 in Review
0 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q1 2023, worth a combined $0 — down 100% from $126M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of IBER and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Glazer Capital LLC, exiting entirely with an estimated $13.4M sold.
- 0 institutional investors held Ibere Pharmaceuticals (IBER) as of Q1 2023, down from 47 in Q4 2022.
- Funds reported $0 of Ibere Pharmaceuticals stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Ibere Pharmaceuticals positions in Q1 2023 and 47 closed out, a net change of -47 holders.
- The largest Ibere Pharmaceuticals seller in Q1 2023 was Glazer Capital LLC, an estimated $13.4M sold.
Based on aggregated 13F filings for Q1 2023.